Navigation Links
Implant-based cancer vaccine is first to eliminate tumors in mice
Date:11/25/2009

CAMBRIDGE, Mass. -- A cancer vaccine carried into the body on a carefully engineered, fingernail-sized implant is the first to successfully eliminate tumors in mammals, scientists report this week in the journal Science Translational Medicine.

The new approach, pioneered by bioengineers and immunologists at Harvard University, uses plastic disks impregnated with tumor-specific antigens and implanted under the skin to reprogram the mammalian immune system to attack tumors. The new paper describes the use of such implants to eradicate melanoma tumors in mice.

"This work shows the power of applying engineering approaches to immunology," says David J. Mooney, the Robert P. Pinkas Family Professor of Bioengineering in Harvard's School of Engineering and Applied Sciences and Wyss Institute for Biologically Inspired Engineering. "By marrying engineering and immunology through this collaboration with Glenn Dranoff at the Dana-Farber Cancer Institute, we've taken a major step toward the design of effective cancer vaccines."

Most cancer cells easily skirt the immune system, which operates by recognizing and attacking invaders from outside the body. The approach developed by Mooney's group redirects the immune system to target tumors, and appears both more effective and less cumbersome than other cancer vaccines currently in clinical trials.

Conventional cancer vaccinations remove immune cells from the body, reprogram them to attack malignant tissues, and return them to the body. However, more than 90 percent of reinjected cells have died before having any effect in experiments.

The slender implants developed by Mooney's group are 8.5 millimeters in diameter and made of an FDA-approved biodegradable polymer. Ninety percent air, the disks are highly permeable to immune cells and release cytokines, powerful recruiters of immune-system messengers called dendritic cells.

These cells enter an implant's pores, where they are exposed to antigens specific to the type of tumor being targeted. The dendritic cells then report to nearby lymph nodes, where they direct the immune system's T cells to hunt down and kill tumor cells.

"Inserted anywhere under the skin -- much like the implantable contraceptives that can be placed in a woman's arm -- the implants activate an immune response that destroys tumor cells," Mooney says.

The technique may have powerful advantages over surgery and chemotherapy, and may also be useful in combination with existing therapies. It only targets tumor cells, avoiding collateral damage elsewhere in the body. And, much as an immune response to a bacterium or virus generates long-term resistance, researchers anticipate cancer vaccines will generate permanent and body-wide resistance against cancerous cells, providing durable protection against relapse.

Mooney says the new approach's strength lies in its ability to simultaneously regulate the two arms of the human immune system: one that destroys foreign material and one that protects tissue native to the human body. The implant-based vaccine recruits several types of dendritic cells that direct destructive immune responses, creating an especially potent anti-tumor response.

"This approach is able to simultaneously upregulate the destructive immune response to the tumor while downregulating the arm of the immune system that leads to tolerance," Mooney says. "In cancer, this latter arm is typically a limiting feature of immunotherapies, since it can extinguish vaccine activity and afford tumors a degree of protection."


'/>"/>

Contact: Steve Bradt
steve_bradt@harvard.edu
617-496-8070
Harvard University
Source:Eurekalert

Related medicine news :

1. Implantable Cancer Vaccine Shows Promise
2. Lung Cancer Alliance-California Releases 2nd Annual State-Specific Report Card On Lung Cancer
3. Natural Soy Component May Help Treat Colon Cancer
4. Cetuximab Helps Treat Colorectal Cancer
5. Holistic and Western Medicine Combined Can Fight Cancer
6. Researchers identify proteins in lung cancer cells that may provide potential drug targets
7. Sky Foundation, Inc. Raises More Than $100,000 to Find a Test for Early Detection of Pancreatic Cancer
8. Baylor Sammons Cancer Center Joins One of Nations Largest Cancer Clinical Trials Groups
9. Protein from pregnancy hormone may prevent breast cancer
10. Childrens Hospital Oakland scientists discover soy component may be key to fighting colon cancer
11. New device enables early detection of cancerous skin tumors -- Ben Gurion U.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... June 25, 2017 , ... CareSet Labs released the Root ... Orleans. This is a new, greatly improved version of the Doctor Referral teaming dataset ... by Fred Trotter and subsequently called the the “Doctor Referral Dataset” as released by ...
(Date:6/24/2017)... ... June 24, 2017 , ... Dr. Mitchell Mehlman and his ... Lake Ronkonkoma, Dental365 offers patients high-quality and affordable routine and emergency dental care. ... fit into their patients’ busy lifestyles. Dental365 also gladly work with most insurance ...
(Date:6/23/2017)... ... 2017 , ... By scoring 100% for fiscal management and accountability, the Arthritis ... charity evaluator, Charity Navigator, validating ANRF's work as a top charity in America. , ... Navigator and earns ANRF a spot on their “ 10 Charities Worth Watching ” ...
(Date:6/23/2017)... ... June 23, 2017 , ... Military Connection friend ... entry to the JFK Virgin Atlantic lounge. , Bensko is no stranger to ... years ago, Bensko dedicated her life to supporting our wounded veterans. A world-class photographer, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Georgia ... Sept. 18 to 20. , The two-day conference is focused on advancing scientific ... of improving patients’ lives and eliminating racial breast cancer-related disparities. The conference theme ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... 8, 2017  StatLab Medical Products ("StatLab" ... manufacturer of diagnostic supplies for the anatomic ... & Company LP ("Cressey & Company"), a ... growth-focused investment in the Company. Cressey & ... from selling shareholder, Prairie Capital, L.P., with ...
(Date:6/7/2017)... 6, 2017  Diplomat Specialty Infusion Group, a brand of Diplomat ... its Iowa location. The ... now features an ISO 7 cleanroom—the standard needed to compound intravenous ... low level of pollutants. "Our ... and better serve our Iowa patients," said ...
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
Breaking Medicine Technology: